Enliven Therapeutics, Inc. (ELVN)
NASDAQ: ELVN · Real-Time Price · USD
27.39
-0.38 (-1.37%)
At close: Mar 16, 2026, 4:00 PM EDT
26.86
-0.53 (-1.94%)
After-hours: Mar 16, 2026, 7:17 PM EDT
Company Description
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer.
Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors.
The company was founded in 2019 and is headquartered in Boulder, Colorado.
Enliven Therapeutics, Inc.
| Country | United States |
| Founded | 2016 |
| IPO Date | Mar 12, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 60 |
| CEO | Richard Fair |
Contact Details
Address: 6200 Lookout Road Boulder, Colorado 80301 United States | |
| Phone | 720 647 8519 |
| Website | enliventherapeutics.com |
Stock Details
| Ticker Symbol | ELVN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 1672619 |
| CUSIP Number | 29337E102 |
| ISIN Number | US29337E1029 |
| Employer ID | 81-1523849 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Richard A. Fair | Chief Executive Officer, President and Director |
| Samuel S. Kintz M.B.A. | Co-Founder and Head of Pipeline |
| Dr. Joseph P. Lyssikatos Ph.D. | Co-Founder and Chief Scientific Officer |
| Dr. Helen Louise Collins M.D. | Chief Medical Officer |
| Anish Patel Pharm.D. | Co-Founder and Chief Operating Officer |
| Benjamin Hohl | Chief Financial Officer and Head of Corporate Development |
| Dr. Galya D. Blachman Esq., Ph.D. | Chief Legal Officer and Head of Business Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 9, 2026 | 144 | Filing |
| Mar 6, 2026 | 144 | Filing |
| Mar 3, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 3, 2026 | 10-K | Annual Report |
| Mar 3, 2026 | 8-K | Current Report |
| Feb 18, 2026 | 144 | Filing |
| Feb 17, 2026 | 144 | Filing |
| Feb 17, 2026 | 144 | Filing |
| Feb 17, 2026 | 144 | Filing |
| Feb 17, 2026 | SCHEDULE 13G | Filing |